Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor
Status:
Not yet recruiting
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021)
in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer
are:
- Whether the Pimicotinib(ABSK021) works well in patients with TGCT.
- Whether the Pimicotinib(ABSK021) is safe in patients with TGCT.
Participants will be asked to complete the study procedures:
- Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike
substance that contains no active drug) about 24 weeks in study part 1.
- Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2.
- Complete the study procedures speficied in the protocol, which is guided by researchers.